.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Cellares’ automated cell therapy production platform, known as the Cell Shuttle,...
And more biotech news stories, brought to you by The Readout.
Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim,...
Directors of five NIH institutes have been placed on administrative leave or off...
Get your daily dose of health and medicine every weekday with STAT’s free newsle...
Get your daily dose of health and medicine every weekday with STAT’s free newsle...
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...
Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, payi...
Edgewise Therapeutics' hypertrophic cardiomyopathy asset has resulted in “rapid ...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Joint HTAb-regulatory perspectives on understanding evidence challenges, managin...
Atsena Therapeutics has raised $150 million in an oversubscribed series C financ...
Analysts appeared unfazed by the news that a patient treated with Cabaletta Bio’...
Human medicines European public assessment report (EPAR): BroPair Spiromax, salm...
The ruling was issued for a pair of lawsuits brought against the FDA by the Amer...
Cell therapy veteran Arie Belldegrun is expanding his empire, bringing in two ne...
Two investment firms have acquired large stakes in global CRO Novotech, the Sing...
Tolvaptan product-specific bioequivalence guidance
Opinion/decision on a Paediatric investigation plan (PIP): Quviviq, Daridorexant...
Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, Azilsartan me...
“As a doctor who is very much a writer, I feel a sense of dread and even grief a...
“If you just looked at the economics of this, vaccines are one of the few ways w...